M2 Europharma articles from April 2002

M2 Europharma archives from April 2002

MediGene submits drug application to German authorities.(Brief Article)
April 30, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The German biotechnology company MediGene AG has submitted a marketing authorisation application with the German health authorities for its Leuprogel Three Month depot product. ...

WHO selects Novartis' malaria drug for essential medicines list.(World Health Organization)(Brief Article)
April 30, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The World Health Organization (WHO) has added Coartem, a new malaria treatment from the Swiss-based pharmaceutical group Novartis AG, to its Model List of Essential Medicines. ...

Epigenomics and Biopsytec license genetic-based technologies.(Brief Article)
April 30, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The German biotechnology companies Epigenomics AG and Biopsytec Holding AG have signed a cross-licensing agreement. Under the agreement Epigenomics gets exclusive rights to use...

US health authorities approve AstraZeneca's new breast cancer treatment.(Brief Article)
April 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc has received approval from the US Food and Drug Administration for Faslodex, its new breast cancer drug. Faslodex, which is administered...

NeuroSearch cancels sickle cell anaemia project.(Brief Article)
April 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish biotechnology firm NeuroSearch A/S has decided not to initiate the planned clinical phase II study of its NS3728 compound as a treatment of sickle cell anaemia, a lethal disease...

Pharmacia buys AT&T's headquarters.(Brief Article)
April 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US-Swedish drug firm Pharmacia Corp has signed an agreement to purchase AT&T's headquarters in New Jersey for USD200m. The facility, which offers approximately 1.3m square feet of...

EU medicines watchdog to investigate allergy drug.(Brief Article)
April 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The European Agency for the Evaluation of Medicinal Products has launched a safety review of Schering-Plough's allergy drug Clarityn. The safety review comes after reports from Sweden...

Medigene's drug development project delayed.(Brief Article)
April 25, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The German biotechnology company MediGene AG has halted the phase II clinical trial for Etomoxir, its drug candidate for the treatment of congestive heart failure. MediGene says that...

Finnish medicines agency launches drug information service.(Brief Article)
April 25, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Finland's National Agency for Medicines has begun to publish product information about drugs at its web site. Initially the service will give access to information on approximately...

AstraZeneca reports 11% increase in first quarter sales.(Brief Article)
April 25, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc has reported sales of USD4.42bn in the first quarter, compared to USD3.99bn in the same period last year. The stomach ulcer drug Losec has...

Physician Sales and Service to distribute Medisys' test strips.(Medisys PLC's subsidiary Hypoguard signs agreement)(Brief Article)
April 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Hypoguard, the US subsidiary of the UK-based medical equipment supplier Medisys Plc, has signed a distribution agreement with Physician Sales and Service Inc (PSS), a US-based specialty...

Phytopharm's dementia treatment enters final phase of clinical study.(Phytopharm PLC)(Brief Article)
April 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The British biotechnology company Phytopharm Plc has launched the final stage of a clinical study of its new drug, P58. P58 is an oral treatment for age-related cognitive dysfunction,...

Indian company gets approval to produce drugs for UK market.(Brief Article)
April 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK Medicines Control Agency (MCA), the regulatory authority responsible for overseeing the drug development process in Britain, has approved one of the manufacturing facilities of the...

Pharmacia reports 3% sales drop in first quarter.(Brief Article)(Statistical Data Included)
April 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US-Swedish pharmaceuticals group Pharmacia Corp has reported net sales of USD3.1bn for the first quarter, a 3% decrease from the same quarter last year. Pharmacia says that the...

Pliva expands to Italy.(company operations expansion details)(Brief Article)
April 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Croatian pharmaceutical company Pliva has launched business operations in Italy. Pliva established an Italian subsidiary, with headquarters in Milan, in October 2001. Since then...

Roche and Isotechnika sign drug development agreement.(Roche Holding AG contracts with Isotechnika Inc)(Brief Article)
April 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swiss pharmaceutical group Roche Holding AG and the Canadian life sciences company Isotechnika Inc have signed an agreement to jointly develop Isotechnika's transplant drug,...

AstraZeneca to apply for non-prescription sales of Losec in USA.(Brief Article)
April 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc and the US consumer products giant Procter & Gamble Co are reportedly planning to jointly ask an expert panel of the US Food and Drug...

Lundbeck's antidepressant drug gets competitor in German market.(Omega Farma's Citalopram tablets)(Brief Article)
April 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Icelandic drug manufacturer Delta reports that the German pharmaceutical companies Merck, Ratiopharm, Biochemie, Temmler Pharma, STADA and Azupharma have begun the marketing in Germany...

GlaxoSmithKline releases new formulation of Paxil drug.(SkyePharma PLC license)(Brief Article)(Product Announcement)
April 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK pharmaceutical giant GlaxoSmithKline Plc has made available a new formulation of its Paxil (paroxetine HCI) depression drug. The new formulation, Paxil Controlled Release...

Elan to invest in new Irish plant.(Elan Corporation PLC)(Brief Article)
April 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Irish pharmaceutical company Elan is to invest USD50-60m in a new drug production plant in southern Ireland. Elan will purchase the facilities vacated by US-based General...

Meda purchases drugs from Wyeth.(license acquisition details)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish specialty pharmaceuticals company Meda AB has acquired a range of drugs from the US-based pharmaceutical company Wyeth. The purchased products include drugs from the...

AstraZeneca licenses bioinformatics tool from Cellomics.(contract details)(Brief Article)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc has signed a licensing agreement with the US-based drug discovery technologies developer Cellomics Inc. Under the agreement AstraZeneca...

US authorities approve Smith & Nephew's surgery instruments and software.(Brief Article)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The British medical devices firm Smith & Nephew Plc has received clearance from the US Food and Drug Administration to market its specially-designed computer-assisted instruments and...

GlaxoSmithKline acquires Hungarian vaccine manufacturing facility.(acquisition details)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK pharmaceutical giant GlaxoSmithKline Plc has acquired the Hungarian-based vaccine manufacturing facilities of Human Serum and Medicine Manufacturing Co Ltd, an affiliate of Israel's...

Diamyd posts SEK7.8m operating loss in December-February period.(Brief Article)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Swedish pharmaceutical company Diamyd Medical AB has reported a turnover of SEK393,000 for the December 2001-February 2002 period, the second quarter in its 2001/2002 financial year,...

Swiss authorities approve licence extension of Novartis' Glivec drug.(company license detail)(Brief Article)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Switzerland's health authority Swissmedic has given the Swiss-based pharmaceuticals group Novartis AG approval to market its Glivec drug as a treatment of adult patients with...

PPL Therapeutics licenses animal cloning technology.(from Advanced Cell Technology Inc)(Brief Article)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US biotechnology firm Advanced Cell Technology Inc (ACT) has signed a licensing agreement with PPL Therapeutics Plc, the British biotechnology company that cloned Dolly the Sheep. ...

Generic version of Lundbeck's Cipramil launched in Denmark.(Brief Article)(Product Announcement)
April 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Gea Farmaceutisk Laboratorium has introduced a generic copy of Cipramil, an antidepressant drug produced by the Danish pharmaceutical company H. Lundbeck A/S, in Denmark. The generic...

Medivir signs licensing agreement with Roche.(non-nucleoside reverse transcriptase inhibitor HIV/AIDS treatment)(Brief Article)
April 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish pharmaceutical research company Medivir has outlicensed its new HIV/AIDS treatment to the Swiss pharmaceutical group Roche Holding AG. The HIV/AIDS treatment, a...

Pyrosequencing launches new analysis system.(PSQ HS 96A System)(Brief Article)
April 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Swedish-based genetic analysis systems developer Pyrosequencing AB has introduced a new product for single nucleotide polymorphism (SNP) and mutation analysis. The product, PSQ HS...

US authorities give priority status to AstraZeneca's licence extension application.(seeks new use for breast cancer drug)(Brief Article)
April 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc reports that the US Food and Drug Administration has granted a six-month Priority Review Status to the supplemental new drug application...

Biotie Therapies, Contral Pharma and Carbion agree to merge.(combined entity will be named Biotie Therapies Corp)(Brief Article)(Statistical Data Included)
April 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Finnish drug development company Biotie Therapies Corp has signed an agreement to merge with the Finnish biotechnology firm Contral Pharma and its subsidiary Carbion Inc. The deal...

Karo Bio gets European patent for nuclear receptor.(Brief Article)
April 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish pharmaceutical company Karo Bio AB says it has received a European patent for its new drug discovery target for the treatment of atherosclerosis, a cardiovascular disease. ...

Photocure challenges validity of Australian photodynamic therapy patent.(Brief Article)
April 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Norwegian biotechnology company PhotoCure ASA has filed papers in an Australian court to invalidate a patent granted in Australia to Canada's Queens University. Queen's...

Pharmexa unveils details of licensing agreement with GlaxoSmithKline.(Pharmexa A/S)(GlaxoSmithKline PLC)(Brief Article)
April 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish biotechnology company Pharmexa A/S reports that animal toxicology studies of its new AutoVac HER-2 Protein therapeutic vaccine will commence this month to be followed by initial...

Orion and Quintiles Transnational to form drug development venture.(Orion Corporation Ltd.)(Quintiles Transnational Corp.)(Brief Article)
April 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Finnish pharmaceutical group Orion Corp and the US-based pharmaceutical services provider Quintiles Transnational Corp have signed a letter of intent to establish a drug development...

Genmab reports positive results from psoriasis drug trial.(Genmab A/S )(Brief Article)
April 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish biotechnology company Genmab A/S claims that several patients suffering from the skin disease psoriasis have experienced a long-lasting improvement of their condition after...

Genmab posts net loss of DKK99.4m for first quarter.(Genmab A/S )(Brief Article)
April 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish biotechnology company Genmab A/S has reported an operating loss of DKK106.6m for the first quarter of 2002, compared to an operating loss of DKK35.2m in the same period last year....

Icelandic government decides to support deCODE genetics.(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Iceland's government is to introduce to the parliament a bill that would enable the minister of finance to guarantee a convertible bond offering worth up to USD200m by the Icelandic...

EU Commission approves Pharmacia's injectable pain medication.(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US-Swedish pharmaceuticals group Pharmacia Corp has received marketing authorisation from the European Commission for its Dynastat drug as a short-term treatment of postoperative pain....

UK drugs watchdog recommends Zyban for NHS use.(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Britain's medicines advisory body, the National Institute for Clinical Excellence (NICE), has recommended that the National Health Service should be permitted to prescribe GlaxoSmithKline...

Novartis introduces ERT patch in Germany.(estrogen replacment therapy drug -- estradot)(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swiss-based pharmaceuticals group Novartis AG has launched Estradot, its estrogen replacement therapy (ERT) for the treatment of menopausal symptoms in women, in Germany - the first...

Icelandic government's support for deCODE upsets other companies.(deCODE Genetics Inc.)(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Icelandic government's recent decision to support deCODE genetics in its efforts to set up a new unit in Iceland has reportedly been met with mixed reactions from the country's other...

Active Biotech begins study of multiple sclerosis drug.(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish biotechnology company Active Biotech AB has launched a phase II clinical study of its new drug for the treatment of multiple sclerosis (MS). Active Biotech says that the...

Bavarian Nordic forms vaccine partnership with PowderJect.(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish biotechnology company Bavarian Nordic A/S has won a EUR17.6m contract to supply vaccines to the UK pharmaceutical firm PowderJect Pharmaceuticals Plc. Bavarian expects...

Genmab and Paradigm Therapeutics form drug development partnership.(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish biotechnology company Genmab A/S and the British drug discovery firm Paradigm Therapeutics Ltd have joined forces to develop new antibody therapeutic products. The...

Akzo Nobel's new anti-depressant drug to be delayed.(Brief Article)
April 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Dutch chemicals group Akzo Nobel NV reports that its Organon healthcare unit will probably not be able to launch the Ariza anti-depressant drug as planned in 2002. Organon has...

Novo Nordisk warns of lower sales and operating profit for 2002.(Brief Article)
April 10, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Danish biotechnology company Novo Nordisk A/S reports that its sales in the first quarter of 2002 have been lower than anticipated and that full-year sales are not likely to reach the...

Xylifloss' dental floss becomes available in Rite Aid's stores.(Brief Article)
April 10, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US pharmacy chain Rite Aid Corp has introduced Xylifloss, a dental flosser from the Finnish dental care products maker Xylifloss Ltd, in its approximately 3,500 stores across the US....

Smiths Group to co-market Medisys' medical safety products.(Brief Article)
April 10, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK-based medical equipment supplier Medisys Plc has signed a partnership agreement with the British industrial manufacturer Smiths Group Plc. Under the agreement, Smiths becomes...

Aventis sues Impax Laboratories over allergy drug patent.(Brief Article)
April 10, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Aventis Pharmaceuticals Inc, a US subsidiary of the French-German drugs and chemicals group Aventis SA, has filed a patent infringement suit against the California-based pharmaceutical...

AstraZeneca's US court case postponed.(Brief Article)
April 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A patent case due to start yesterday (8 April) in a New York court between the Anglo-Swedish drug group AstraZeneca Plc and four generic drug manufacturers, among them Florida-based Andrx...

AstraZeneca submits licence extension application for cancer drug.(Brief Article)
April 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Anglo-Swedish drug group AstraZeneca Plc has submitted an application to the European Union's health authorities for a licence extension of its Arimidex drug. Arimidex is already...

British Biotech's leukaemia drug gets orphan medicine status.(Brief Article)
April 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK biotechnology company British Biotech reports that the European Commission has designated its E21R leukaemia drug as an orphan medicinal product in the European Union. The...

Xenova begins cocaine vaccine trial.(Brief Article)
April 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK-based biotechnology company Xenova Group Plc has begun patient dosing in a phase IIa dose escalation trial of TA-CD, its new vaccine being developed for the treatment of cocaine...

Axcan Pharma to acquire France's Laboratoire du Lacteol du Docteur Boucard.(Brief Article)(Statistical Data Included)
April 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Canadian pharmaceutical company Axcan Pharma Inc has signed an agreement to acquire all of the shares of Laboratoire du Lacteol du Docteur Boucard SA, a French firm specialised in the...

deCODE hopes for financing help for new pharmaceutical unit.(government of Iceland considers helping to finance new venture from deCODE genetics Inc.)(Brief Article)
April 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The government of Iceland is reportedly considering whether it should help finance a pharmaceutical unit that the Icelandic biotechnology company deCODE genetics plans to establish in...

Boehringer Ingelheim and Shionogi form Japanese joint venture.(Boehringer Ingelheim Shionogi Vetmedica Company Ltd.)(Brief Article)
April 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The German pharmaceutical company Boehringer Ingelheim and Japan's Shionogi & Co Ltd have established a joint venture called Boehringer Ingelheim Shionogi Vetmedica Co Ltd. The new...

Lyfjathroun and Bespak team to develop nasal delivery drugs.(Brief Article)
April 5, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Icelandic pharmaceutical company Lyfjathroun has signed a partnership agreement with the British drug delivery technologies developer Bespak. Under the agreement the companies...

Swedish study compares drug prices in Europe.(Brief Article)
April 5, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Swedish medicine prices are on average 4% lower than in other European countries and 2% lower than in the other Nordic countries, according to a new study by the Swedish National Social...

AstraZeneca returns compound rights to Cardiome Pharma.(Brief Article)
April 5, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Canadian drug discovery/development company Cardiome Pharma Corp has received notice from the Anglo-Swedish drug manufacturer AstraZeneca Plc that it does not intend to proceed with...

Roche forms new biotechnology company. (Roche Holding AG, BioXell).(Brief Article)
April 5, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swiss pharmaceutical group Roche Holding AG has created a new independent biotechnology company called BioXell. Formed by a spin-off of Roche's Italian-based research and...

Industrivarden divests minority stake in Lundbeck.(Brief Article)
April 4, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish holding company Industrivarden has sold its entire holding in the Danish pharmaceutical company H. Lundbeck A/S. Industrivarden sold its 8,427,400 Lundbeck shares, which...

French scientists clone rabbits.(Brief Article)
April 4, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The French biotechnology companies BioProtein Technologies and Vivalis report that they have succeeded, together with France's National Agricultural Research Institute, in cloning the...

Elan and UCB to co-promote migraine drug.(Brief Article)
April 4, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Irish pharmaceutical company Elan Corp Plc and UCB Pharma Inc, the US affiliate of the Belgian chemicals and pharmaceuticals firm UCB, have agreed to co-promote Elan's Frova migraine...

Nobel Biocare establishes Swiss holding structure.(Brief Article)
April 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swedish dental implants and prosthetics producer Nobel Biocare AB has decided to set up a holding structure for the company in Switzerland and to list the new parent firm both on the...

Guidant licenses Novartis' drug.(Brief Article)
April 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Swiss pharmaceutical group Novartis AG has signed a worldwide co-exclusive licensing agreement with US-based Guidant Corp for its everolimus drug. The agreement gives Guidant the...

Galen acquires two Bristol-Myers Squibb products.(an antibiotic and a skin cream)(Brief Article)
April 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The Northern Ireland pharmaceuticals group Galen Holdings has acquired the rights to two products - Duricef and Moisturel - from the US-based healthcare firm Bristol-Myers Squibb Co. ...

BioMarin and Genzyme file for EU approval for new drug.(BioMarin Pharmaceutical Inc., Genzyme General Corp.)(Brief Article)
April 2, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The US biotechnology companies BioMarin Pharmaceutical Inc and Genzyme General Corp have filed an application with the European Union's regulatory authorities for approval to market their...

Shire seeks EU approval for Essential Thrombocythemia treatment.(Shire Pharmaceuticals Group PLC seeks marketing approval for Xagrid in European Union)(Brief Article)
April 2, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The British pharmaceutical company Shire Pharmaceuticals Group Plc has submitted a marketing authorisation application for its XAGRID (anagrelide) drug with the European Medicine...

Aventis to give smallpox vaccine to USA for emergency use.(Aventis Pasteur S.A.)(Brief Article)
April 2, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Aventis Pasteur, a unit of the French-German drugs and chemical group Aventis SA, has decided to donate its store of about 85m doses of smallpox vaccine to the US government for fighting...

Novo Nordisk and Rite Aid team to improve diabetes care in USA.(Novo Nordisk Pharmaceuticals)(Brief Article)
April 1, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Novo Nordisk Pharmaceuticals Inc, a unit of the Danish pharmaceutical company Novo Nordisk A/S, has signed a collaboration agreement with the US pharmacy chain Rite Aid Corp. Under...

Scientists develop new Parkinson's disease treatment.(Brief Article)
April 1, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A team of US and Swedish scientists reports that is has conducted successful tests on rats of a new treatment for Parkinson's disease. The researchers from the University of Florida...